Fierce Healthcare
DECEMBER 10, 2021
Health services M&A deals surged in 2021. Here are key trends that could impact deal-making next year, PwC reports. hlandi. Fri, 12/10/2021 - 14:55.
pharmaphorum
DECEMBER 10, 2021
AbbVie has ended speculation about what it will charge for its newly-approved Vuity therapy for presbyopia, a sight condition characterised by difficulty in focusing on near objects. The company told CBS it will charge around $80 for a 30-day supply of Vuity , a once-daily eyedrop formulation of muscarinic cholinergic agonist pilocarpine intended as an alternative to reading glasses, contact lenses or laser eye surgery.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Healthcare
DECEMBER 10, 2021
From 340B to short-term health plans: Here are the top 4 regulations to watch for in 2022. rking. Fri, 12/10/2021 - 16:44.
pharmaphorum
DECEMBER 10, 2021
Already scrambling to refile its obeticholic acid (OCA) drug for non-alcoholic steatohepatitis (NASH) after the FDA rejected it last year, Intercept Pharma was hoping for more luck in Europe, but has now withdrawn its EU marketing application. Intercept had been hoping to extend the review period in the EU to allow time for results from an ongoing to phase 3 trial to come in, now due in the first quarter of next year, but conceded defeat yesterday.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Healthcare
DECEMBER 10, 2021
Study: Medicaid expansion not a 'panacea' for solving critical access hospitals' financial woes. pminemyer. Fri, 12/10/2021 - 12:11.
pharmaphorum
DECEMBER 10, 2021
US remote healthcare specialist ChronWell has raised $6 million from investors that will be used to accelerate the rollout of its patient management programmes for people with liver and gastrointestinal diseases. The financing involved new and existing backers, which have not been identified, and will be directed mainly to LIVErHEALTHY, a digital health programme that was launched by ChronWell last year.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
pharmaphorum
DECEMBER 10, 2021
Roche’s closely-watched combination of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq has shown long-term efficacy in an ongoing trial in lung cancer, adding to the evidence that two immunotherapies may be better than one. Like PD-L1, TIGIT is thought to act as a molecular brake that stops T cells from attacking tumours, and tiragolumab is currently leading the pack among drugs targeting the immune checkpoint.
Fierce Healthcare
DECEMBER 10, 2021
Senate passes bill to delay nearly 10% in Medicare cuts expected to start in January. rking. Fri, 12/10/2021 - 10:25.
pharmaphorum
DECEMBER 10, 2021
pharmaphorum’s founder, Dr Paul Tunnah, continues his Frontiers Health Digital Innovators series by speaking with Orion Pharma’s director of digital medicine Sammeli Likkanen. Live from Frontiers Health conference in Milan, Sammeli provides insights into the difference between digital health and digital transformation. He discusses how virtual reality (VR) is changing digital therapeutics, and what Orion’s role is in utilising VR technology.
Fierce Healthcare
DECEMBER 10, 2021
How Morgan Health is making its accountable care pitch to providers. pminemyer. Fri, 12/10/2021 - 15:06.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Marketing Network
DECEMBER 10, 2021
Rita Ribeiro, Product Director, Oncology Marketing, is a marketing leader with 20 years of global and US healthcare experience in pharmaceutical, medical device and services organizations. She has developed and implemented regionalized, integrated strategic plans to increase brand awareness and drive organizational growth across multiple therapeutic areas and service networks.
Pharma Times
DECEMBER 10, 2021
In October 2021, over 356,000 people in England had been waiting for over six weeks for a key diagnostic test
Pharma Times
DECEMBER 10, 2021
The treatments are being offered as an addition to vaccinations to maximise protection against COVID-19
Expert insights. Personalized for you.
125 
Let's personalize your content